Wang Xianling, Xie Yongjian, Yang Huijie, Li Chengxian, Wen Xinru, Chen Simin, Yao Qing, Zheng Congyang, Li Chengwei, He Caiping, Fang Mingxia, Shi Ce, Huang Ang, Zhang Ping, Bai Zhaofang, Zhan Xiaoyan, Xiao Xiaohe
Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China; Senior Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China; Military Institute of Chinese Materia, the Fifth Medical Centre, General Hospital of PLA, Beijing 100039, China.
Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Mol Immunol. 2025 Aug;184:22-31. doi: 10.1016/j.molimm.2025.05.020. Epub 2025 Jun 5.
Psoralidin is a major component of the traditional Chinese medicine Psoraleae Fructus, which is derived from the dried mature fruit of the leguminous plant Psoralea corylifolia L. and possesses many pharmacological effects, including anti-tumor effects. However, the mechanism through which psoralidin protects against hepatocellular carcinoma (HCC) remains unclear. In our study, we found that psoralidin induced pyroptosis and gasdermin E (GSDME) cleavage in HepG2 and Hepa1-6 cells, which were reversed by the caspase-3 inhibitor Z-DEVD-FMK. Moreover, psoralidin induced mitochondrial reactive oxygen species (ROS) production, leading to caspase-3 activation and subsequent GSDME cleavage. Interestingly, psoralidin induced pyroptosis in macrophages via ROS-NLRP3 inflammasome-gasdermin D (GSDMD), leading to the secretion of interleukin (IL)-1β and IL-18, which promoted natural killer (NK) cell activation and its anti-tumor capability. In a mouse model, psoralidin suppressed HCC growth, induced tumor cell pyroptosis, and enhanced tumor infiltration of T and NK cells. Collectively, our data demonstrate that psoralidin induces pyroptosis in tumor cells via ROS/caspase-3/GSDME and triggers pyroptosis in macrophages via ROS/NLRP3 inflammasome/GSDMD, enhancing NK cell anti-tumor ability, suggesting that psoralidin could be used as a potential therapeutic candidate for HCC.
补骨脂素是中药补骨脂的主要成分,补骨脂来源于豆科植物补骨脂干燥成熟果实,具有多种药理作用,包括抗肿瘤作用。然而,补骨脂素预防肝细胞癌(HCC)的机制仍不清楚。在我们的研究中,我们发现补骨脂素在HepG2和Hepa1-6细胞中诱导细胞焦亡和gasdermin E(GSDME)裂解,而这一过程可被半胱天冬酶-3抑制剂Z-DEVD-FMK逆转。此外,补骨脂素诱导线粒体活性氧(ROS)生成,导致半胱天冬酶-3激活及随后的GSDME裂解。有趣的是,补骨脂素通过ROS-NLRP3炎性小体- gasdermin D(GSDMD)在巨噬细胞中诱导细胞焦亡,导致白细胞介素(IL)-1β和IL-18分泌,从而促进自然杀伤(NK)细胞活化及其抗肿瘤能力。在小鼠模型中,补骨脂素抑制HCC生长,诱导肿瘤细胞焦亡,并增强T细胞和NK细胞的肿瘤浸润。总体而言,我们的数据表明,补骨脂素通过ROS/半胱天冬酶-3/GSDME在肿瘤细胞中诱导细胞焦亡,并通过ROS/NLRP3炎性小体/GSDMD在巨噬细胞中触发细胞焦亡,增强NK细胞的抗肿瘤能力,这表明补骨脂素可作为HCC的潜在治疗候选药物。